The UCLA trial has nothing to do with NWBO. Nothing. It will have no bearing on whether NWBO's trial to prove the efficacy of DCVax leads to regulatory approval. It will not benefit NWBO shareholders in any way, regardless of outcome. The UCLA trial intentionally chose to use a generic name for the vaccine instead of DCVax. Dr. Linda Liau cut ties with NWBO a long time ago. She begged out of presenting the top line data at the last minute.

If you are counting on the UCLA trial to benefit NWBO shareholders, you are completely missing the boat.